Literature DB >> 1203887

Coordination complexes of platinum as antitumor agents.

R J Speer, H Ridgway, L M Hall, D P Stewart, K E Howe, D Z Lieberman, A D Newman, J M Hill.   

Abstract

Rosenberg and VanCamp first reported the bacteriostatic and antitumor properties of certain platinum coordination compounds. This pioneering work has led to the synthesis and testing of a large number of related platinum products and the clinical use of cis-dichlorodiammineplatinum (II). This drug has proven very efficacious against a wide variety of mouse tumors when employed as the sole chemotherapeutic agent and has also been combined successfully with other antitumor agents, such as cyclophosphamide and cytosine arabinsoide. Unfortunately, cis-dichlorodiammineplatinum (II) has a low therapeutic index with renal toxicity being the principal limitation of its use. This has prompted the synthesis and testing of many related platinum compounds, of which cis-dichlorobiscyclopentylamine-platinum (II) and the "platinum blues" appear most promising. Experience in the synthesis, purification, and testing of such products will be discussed together with identification of outstanding unsolved problems in this area.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1203887

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  8 in total

1.  Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container's material.

Authors:  M Pujol Cubells; J Prat Aixela; V Girona Brumos; S Duran Pou; M Villaronga Flaque
Journal:  Pharm World Sci       Date:  1993-02-19

2.  Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium (IV) compounds. A new class of antineoplastic agents.

Authors:  H J Keller; B Keppler; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

Review 3.  An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures.

Authors:  George J Dugbartey; Luke J Peppone; Inge A M de Graaf
Journal:  Toxicology       Date:  2016-10-04       Impact factor: 4.221

Review 4.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

5.  Platinum drugs: combined anti-lymphoproliferative and nephrotoxicity assay in rats.

Authors:  S K Aggarwal; J A Broomhead; D P Fairlie; M W Whitehouse
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 6.  Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues.

Authors:  P C Hydes; M J Russell
Journal:  Cancer Metastasis Rev       Date:  1988-04       Impact factor: 9.264

7.  Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer.

Authors:  M V Alvarez; G Cobreros; A Heras; M C Lopez Zumel
Journal:  Br J Cancer Suppl       Date:  1978-06

8.  Acetate-bridged platinum(III) complexes derived from cisplatin.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2012-09-04       Impact factor: 5.165

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.